231 results
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
9 May 24
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results
8:05am
costs, non-clinical and preclinical services, clinical trials and consulting and (ii) $0.4 million in higher employee compensation and benefits … the development steps of NeuroBo’s current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
30 Apr 24
Other Events
8:30am
regulatory approval through the development steps of NeuroBo's current and future product candidates, the ability to realize the benefits of the license
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
17 Apr 24
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
8:30am
to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo
8-K
EX-99.1
jxmhe9n0x5hl5itcinp
16 Apr 24
Other Events
4:30pm
8-K
EX-99.1
48d6n
1 Apr 24
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
8:30am
8-K
EX-99.1
ecpzm1k8
28 Mar 24
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
fxumw54b02h1vyn
13 Mar 24
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
8:30am
8-K
1s6mv3s6t0c8i h7
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
EX-10.1
0fp1q5nr bi
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
EX-99.1
ovig1j6v 40
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
EX-99.1
54vqc
29 Feb 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
8:30am